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Abstract
A formal synthesis of leustroducsin B has been completed. The synthesis relies upon a recently
developed Reformatsky/Claisen condensation of silyl glyoxylates and enantioenriched β-lactones
that establishes two of the molecule’s three core stereocenters and permits further elaboration to an
intermediate in Imanishi’s synthesis via reliable chemistry (Prasad reduction, asymmetric
pentenylation, Mitsunobu inversion).
The leustroducsin1 and phoslactomycin2 families of natural products were first isolated in
1993 by Kohama et al. from the culture broth of Streptomyces platensis and were later found
to exhibit interesting antifungal, antibacterial, and antitumor activities.1b,2b,3ab These natural
products boast intriguing molecular architectures: common features include a highly
congested and functionalized core flanked by dihydropyrone and cyclohexyl moieties and a
central tertiary alcohol with vicinal phosphate and aminoethyl substituents.
The individual members of this natural product family are largely distinguished by the
substituent present at C18 of the cyclohexyl ring (Figure 1), a structural feature which has
been shown to partially modulate a variety of biological activities attributed to the
leustroducsins and phoslactomycins.1a,2a Particularly notable is leustroducsin B (C18: 6-
methyloctanoate), which has shown potent in vitro induction of granulocyte-CSF and
granulocyte-macrophage-CSF production by KM-102 cells,1a,3c,3d in vivo augmentation of
host resistance in E. coli infections,3c and induction of thrombocytosis in mice.3e
A number of synthetic studies have been performed on the leustroducsin4–6 and
phoslactomycin7 families of molecules, including total syntheses of leustroducsin B by
Fukuyama (2003)4 and Imanishi (2006)5 and a formal synthesis by Cossy (2008).6 This
Letter details a formal synthesis of leustroducsin B enabled by a tandem Reformatsky/
Claisen condensation of silyl glyoxylate 28 and enantioenriched β-lactones9 recently
invented for the purpose of preparing the leustroducsin core functionality. The three-
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component coupling shown in Scheme 1 proceeded reliably on multigram scale to give the
derived Claisen products in 61% (1a, SiR3 = TES) or 67% (1b, SiR3 = TBS) yield with
excellent diastereoselectivity (>20:1) through the transfer of stereochemical information
from the β-lactone. Access to the correct C8-configuration required the use of the illustrated
(S)-β-lactone, a circumstance leading to a temporary stereochemical error at C11.10
The 11S alcohol was advantageously deployed to establish the correct configuration of the
C9 hydroxyl via a directed Prasad reduction11 of the C9 ketone to the corresponding syn-
diol and facilitate the evaluation of a possible late-stage Mitsunobu reaction. Excellent
selectivity for the propargylic site was observed (>20:1) in the synthesis of 3, achieving both
stereochemical correction at C11 and differentiation of the C9 and C11 hydroxyls. While we
encountered difficulties in hydrolysis of the chloroacetate under basic and acidic conditions
at this early stage due to competing lactonization and silyl ether deprotection/retro-aldol
pathways, we were pleased to observe clean phosphorylation vicinal to the hindered
quaternary center (3 → 4, Scheme 2). We therefore chose to delay this sequence until a
stage at which the resulting phosphate would survive the remaining transformations in the
synthesis and when the corresponding chloroacetate might be more amenable to hydrolysis.
Additionally, the TES ether was selected for protection of the C8 hydroxyl group to avoid a
tenuous removal of the more robust silyl ether later in the synthesis.
The syn-diol was protected as the acetonide (Scheme 3), and we sought to convert the
resulting diester 5 to a suitable precursor for introduction of the dihydropyrone, amine, and
diene moieties. Reduction of the diester functionality to the corresponding diol 6 required
the use of lithium triethylborohydride at reduced temperatures in CH2Cl2 to suppress
migration of the triethylsilyl group to the vicinal primary hydroxyl. This migration was
exacerbated at higher temperatures, in toluene or Et2O, and when employing standard basic
workup conditions (NaOH/H2O2).10
Selective TBS protection of the more accessible primary hydroxyl group and subsequent
oxidation with Dess-Martin’s periodinane afforded aldehyde 7 in 75% yield over two steps.
Two-carbon homologation to enal 8 was achieved in an excellent yield (88%, 2 steps)
through a Horner-Wadsworth-Emmons/DIBAL-H reduction sequence (Scheme 3).
Although several strategies were investigated, a Brown-type asymmetric pentenylation6,12
proved to be the optimal method for introduction of the dihydropyrone from enal 8, setting
the stereocenters at C4 and C5 and introducing the functionality required for elaboration of
the dihydropyrone. Deprotection of the TMS-protected alkyne (K2CO3/MeOH) and
acryloylation proceeded uneventfully (Scheme 4), but acrylate 9 was found to be inert under
all ring-closing metathesis conditions screened.10 We conjectured that the presence of the
alkyne might be impeding reactivity, as coordination of ruthenium to free alkynes has been
shown to hinder RCM reactions.13 The TMS-protected alkyne was similarly unreactive.14
Protection of the terminal alkyne as the dicobalt hexacarbonyl complex15 allowed alkene
metathesis to proceed at room temperature and afforded dihydropyrone 11 after deprotection
with ceric ammonium nitrate. Few examples of ring-closing metatheses in the presence of
terminal alkyne functionalities exist; only recently has the use of dicobalt hexacarbonyl
alkyne protection been employed to this end.13b,c While the use of an alkyne protecting
group adds two additional steps to the synthesis, its near quantitative introduction and
removal consequently result in minimal loss of material.
Having accomplished the introduction of the dihydropyrone moiety, we focused on the
remaining challenges in the synthesis: (1) introduction of the amine functionality; (2)
stereochemical correction at C11 and subsequent phosphorylation at C9; and (3) conversion
of the terminal alkyne to the requisite Z,Z-diene. At this stage, deprotection of the acetonide
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to reveal the C9/C11 diol was problematic, even when the primary silyloxy substituent was
first converted to a protected amine functionality (via deprotection and Mitsunobu reaction
with a biscarbamate16a,b). The increased stability afforded by a TBS group at C8 allowed for
facile and selective deprotection with propanedithiol and BF3•OEt2 in a model system,17 yet
in the presence of the more labile TES group, only decomposition was observed under
identical conditions.
After evaluating the stepwise introduction of functionalities at this stage, we recognized the
need to access a more easily modified intermediate. In light of the remaining
transformations needed to complete the synthesis, dioxane 11 was converted to dioxolane 13
via the intermediate tetraol 12; the latter was generated by global deprotection with CSA/
MeOH (Scheme 5). Careful purification of the sensitive tetraol 12 through a short plug of
deactivated silica gel was necessary to avoid significant decomposition. Selective silylation
of the primary and propargylic hydroxyl groups could be achieved at low temperature, and
protection of the remaining diol as the acetonide afforded 13 in 73% yield over three steps.
Dioxolane 13 proved far more amenable to selective functionalization and offered relief to
what had appeared to be a synthetic impasse. Protecting group exchange afforded propargyl
alcohol 14, which underwent clean Mitsunobu inversion with chloroacetic acid16 at 60 °C.
The temperature required for this stereochemical correction was found through various
abandoned routes to be dependent on the substitutent at C15 (Scheme 6), likely indicative of
the spatial proximity of the alkyl side chain to the C11 stereocenter.18 Saponification of the
chloroacetate and TBS protection afforded 15 in high yield, which proved a viable precursor
to the vinyl iodide through iodination with NIS/AgNO3 and diimide reduction19 (84%, 2
steps). Selective deprotection of the trityl ether with BCl3 afforded 16, an intermediate
present in Imanishi’s synthesis of leustroducsin B;5 its interception thus constitutes a formal
synthesis of the natural product.
In conclusion, we have completed a formal synthesis of leustroducsin B by preparing vinyl
iodide 16 in 24 steps and an overall 4% yield from hydroxyketone 1. Rapid access to the
core of the molecule was achieved via a tandem Reformatsky/Claisen condensation of a silyl
glyoxylate and an enantioenriched β-lactone, a method relying on unusual 1,4-induced
stereotransmission from the electrophile. This strategy allowed for the use of well-
precedented, synthetically attractive chemistry to establish the molecule’s remaining
stereocenters (Prasad reduction, Brown pentenylation, Mitsunobu reaction). A late-stage
shift in protection strategy (dioxane to dioxolane) permitted the necessary selective
functionalization of polyhydroxylated intermediates and allowed for completion of the
formal synthesis upon reaching an advanced intermediate (16) in Imanishi’s total synthesis.
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Leustroducsin B and Related Compounds
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Evaluation of Late-Stage Strategy
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Synthesis of Dihydropyrone Precursor
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Dioxane to Dioxolane Conversion
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Completion of Formal Synthesis
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